Preclinical studies have demonstrated that reducing GRP78 expression or inhibiting IRE1 in tumor cells enhances macrophage-mediated tumor cell clearance, while PERK inhibition promotes the expansion of M1 macrophages and strengthens the antitumor immune response. The gene discussed is ERN1; the disease is neoplasm.